Aliskiren ameliorates chlorhexidine digluconate‐induced peritoneal fibrosis in rats

Ke, Chun‐Yen; Lee, Chia‐Chi; Lee, Chung‐Jen; Subeq, Yi‐Maun; Lee, Ru‐Ping; Hsu, Bang‐Gee

doi:10.1111/j.1365-2362.2010.02264.x

Cited by 21 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, administration of ACEI and ARB in rats by oral or intraperitoneal route can prevent both functional and structural alterations of the peritoneal membrane by inhibiting TGF‐β and VEGF production . Two recent studies in rats found that intraperitoneal and intravenous renin inhibitor (Aliskiren) improved damage and fibrosis markers, and prevented functional modifications in peritoneal transport . Mineralocorticoid receptor blockade (spironolactone) is also able to ameliorate progression of peritoneal fibrosis and improve peritoneal membrane function in the peritoneal scraping rat model …”

Section: Resultsmentioning

confidence: 99%

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

Ditsawanon

Aramwit

2015

J Clin Pharm Ther

View full text Add to dashboard Cite

Summary What is known and objective Peritoneal dialysis (PD) has been widely used by patients with end‐stage renal disease. However, chronic exposure of the peritoneal membrane to bioincompatible PD solutions, and peritonitis and uraemia during long‐term dialysis result in peritoneal membrane injury and thereby contribute to membrane changes, ultrafiltration (UF) failure, inadequate dialysis and technical failure. Therefore, preserving the peritoneal membrane is important to maintain the efficacy of PD. This article reviews the current literature on therapeutic agents for preserving the peritoneal membrane. Methods A literature search of PubMed was conducted using the search terms peritoneal fibrosis, peritoneal sclerosis, membrane, integrity, preserve, therapy and peritoneal dialysis, but not including peritonitis. Published clinical trials, in vitro studies, experimental trials in animal models, meta‐analyses and review articles were identified and reviewed for relevance. Results and discussion We focus on understanding how factors cause peritoneal membrane changes, the characteristics and mechanisms of peritoneal membrane changes in patients undergoing PD and the types of therapeutic agents for peritoneal membrane preservation. There have been many investigations into the preservation of the peritoneal membrane, including PD solution improvement, the inhibition of cytokine and growth factor expression using renin–angiotensin–aldosterone system (RAAS) blockade, glycosaminoglycans (GAGs), L‐carnitine and taurine additives. In addition, there are potential future therapeutic agents that are still in experimental investigations. What is new and conclusion The efficacy of many of the therapeutic agents is uncertain because there are insufficient good‐quality clinical studies. Overall membrane preservation and patient survival remain unproven in using more biocompatible PD solutions. With RAAS blockade, results are still inconclusive, as many of the clinical studies were retrospective. With GAGs, L‐carnitine and taurine additives, there is no sufficiently long follow‐up clinical study with a large sample size to support its efficacy. Therefore, better quality clinical studies within this area should be performed.

show abstract

Section: Resultsmentioning

confidence: 99%

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

Ditsawanon

Aramwit

2015

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…This may explain the decrease in the myofibroblasts as detected by ␣SMA noticed in group IV of the current study. Aliskiren has been reported to protect against peritoneal fibrosis in rats by decreasing TGF-␤1 production (Ke et al, 2010). Aliskiren attenuated the progression of liver fibrosis and TGF-␤1 expressions in steatohepatitis rat model (Aihara et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice

et al. 2015

View full text Add to dashboard Cite

“…Exogenous chemical stimulants (chlorhexidine alcohol, chlorhexidine ethanol, ChE) may stimulate tissues producing the inflammatory response. There are some studies that showed that repeat intraperitoneal injections of chlorhexidine alcohol could build peritoneal fibrosis model in rats [16][17][18]. Hence, we suppose that repeat local tunica albuginea injections by ChE can build an animal model that is even more in accordance with the PD pathophysiological process.…”

mentioning

confidence: 84%

Repeated Micro-Trauma of the Penile Tunica Albuginea: A New Animal Model of Peyronie's Disease

et al. 2017

View full text Add to dashboard Cite

Objectives: To compare effects of repairing injured tunica albuginea (PTA) of rat penis by single or repeated local injections of chlorhexidine ethanol (ChE) into the PTA and to establish a new animal model of Peyronie's disease (PD). Materials and Methods: Forty-two rats were divided into 7 groups. Rats either served as the normal control group with 1-5 injections of 0.9% saline or they received a single injection, 2, 3, 4, or 5 injections of ChE (0.1% chlorhexidine gluconate plus 15% ethanol dissolved in saline); rats in the positive control group were injected with TGF-β1. At 60 days after the last injection, the intracavernous pressure, degree of penile curvature, and histology were evaluated. Results: Compared with the single injection of the ChE group, we found the following in the repeat ChE injections groups: an increase in the degree of penile curvature, fibrous plaques in the PTA and/or corpus cavernosum, broken elastic fibers, slightly decreased erectile function, and an increased expression of TGF-β1 and αSMA. Conclusions: Repeated ChE injuries of PTA may lead to fibrosis. This represents an excellent model of PD that involves repeated injections of ChE into the local PTA as well as reveals the pathophysiologic mechanism of PD.

show abstract

Aliskiren ameliorates chlorhexidine digluconate‐induced peritoneal fibrosis in rats

Abstract: Background Peritoneal fibrosis (PF) is a recognized complication of long-term peritoneal dialysis (PD) and can lead to ultrafiltration failure. The present study was designed to investigate the protective effects of aliskiren on chlorhexidine digluconate-induced PF in rats.

Cited by 21 publications

References 31 publications

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

Biochemical and histological impact of direct renin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced pulmonary fibrosis in adult mice

Repeated Micro-Trauma of the Penile Tunica Albuginea: A New Animal Model of Peyronie's Disease

Contact Info

Product

Resources

About